ADCs consist of a monoclonal antibody linked to a potent cytotoxic drug, allowing for precise targeting of tumor cells based on specific surface antigens, such as HER2, CD20, and Trop-2 (Shih et al., 2024; Belluomini et al., 2023a). This evidence concerns the gene TACSTD2 and neoplasm.